Literature DB >> 21818144

Clinical trials: Trial design in NASH--realities and challenges.

Paul Angulo.   

Abstract

Entities:  

Mesh：

Year:  2011        PMID： 21818144     DOI： 10.1038/nrgastro.2011.125

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  10 in total

1.  ACP Journal Club: vitamin E, but not pioglitazone, improved nonalcoholic steatohepatitis in nondiabetic patients.

Authors:  A J Sanyal
Journal:  Ann Intern Med       Date:  2010-09-21       Impact factor: 25.391

2.  Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity.

Authors:  Giovanni Musso; Roberto Gambino; Maurizio Cassader; Gianfranco Pagano
Journal:  Ann Med       Date:  2010-11-02       Impact factor: 4.709

3.  Diagnosing steatohepatitis and predicting liver-related mortality in patients with NAFLD: two distinct concepts.

Authors:  Paul Angulo
Journal:  Hepatology       Date:  2011-06       Impact factor: 17.425

4.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Naga Chalasani; Kris V Kowdley; Arthur McCullough; Anna Mae Diehl; Nathan M Bass; Brent A Neuschwander-Tetri; Joel E Lavine; James Tonascia; Aynur Unalp; Mark Van Natta; Jeanne Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  N Engl J Med       Date:  2010-04-28       Impact factor: 91.245

5.  Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality.

Authors:  Zobair M Younossi; Maria Stepanova; Nila Rafiq; Hala Makhlouf; Zahra Younoszai; Ritambhara Agrawal; Zachary Goodman
Journal:  Hepatology       Date:  2011-05-14       Impact factor: 17.425

6.  Long-term follow-up of patients with NAFLD and elevated liver enzymes.

Authors:  Mattias Ekstedt; Lennart E Franzén; Ulrik L Mathiesen; Lars Thorelius; Marika Holmqvist; Göran Bodemar; Stergios Kechagias
Journal:  Hepatology       Date:  2006-10       Impact factor: 17.425

7.  Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial.

Authors:  Joel E Lavine; Jeffrey B Schwimmer; Mark L Van Natta; Jean P Molleston; Karen F Murray; Philip Rosenthal; Stephanie H Abrams; Ann O Scheimann; Arun J Sanyal; Naga Chalasani; James Tonascia; Aynur Ünalp; Jeanne M Clark; Elizabeth M Brunt; David E Kleiner; Jay H Hoofnagle; Patricia R Robuck
Journal:  JAMA       Date:  2011-04-27       Impact factor: 56.272

8.  Endpoints and clinical trial design for nonalcoholic steatohepatitis.

Authors:  Arun J Sanyal; Elizabeth M Brunt; David E Kleiner; Kris V Kowdley; Naga Chalasani; Joel E Lavine; Vlad Ratziu; Arthur McCullough
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

9.  Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial.

Authors:  Valerio Nobili; Melania Manco; Rita Devito; Vincenzo Di Ciommo; Donatella Comparcola; Maria Rita Sartorelli; Fiorella Piemonte; Matilde Marcellini; Paul Angulo
Journal:  Hepatology       Date:  2008-07       Impact factor: 17.425

10.  Final results of a long-term, clinical follow-up in fatty liver patients.

Authors:  Sanne Dam-Larsen; Ulrik Becker; Maria-Benedicte Franzmann; Klaus Larsen; Per Christoffersen; Flemming Bendtsen
Journal:  Scand J Gastroenterol       Date:  2009       Impact factor: 2.423
  10 in total
  3 in total

1.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease.

Authors:  Paul Angulo; David E Kleiner; Sanne Dam-Larsen; Leon A Adams; Einar S Bjornsson; Phunchai Charatcharoenwitthaya; Peter R Mills; Jill C Keach; Heather D Lafferty; Alisha Stahler; Svanhildur Haflidadottir; Flemming Bendtsen
Journal:  Gastroenterology       Date:  2015-04-29       Impact factor: 22.682

2.  Hepatic steatosis and steatohepatitis: Are they really two distinct entities?

Authors:  Cory M Fielding; Paul Angulo
Journal:  Curr Hepatol Rep       Date:  2014-06-01

3.  Machine learning to predict progression of non-alcoholic fatty liver to non-alcoholic steatohepatitis or fibrosis.

Authors:  Sina Ghandian; Rahul Thapa; Anurag Garikipati; Gina Barnes; Abigail Green-Saxena; Jacob Calvert; Qingqing Mao; Ritankar Das
Journal:  JGH Open       Date:  2022-03-08
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.